New guidelines favor varenicline for smoking cessation. Based on the results of a systematic review, new guidelines from the American Thoracic Society strongly recommend the use of varenicline for smoking cessation, rather than the nicotine patch or bupropion. However, varenicline combined with a nicotine patch may be preferable to monotherapy. This is a change from previous guidelines, which did not cite a preference for first-line therapy among any of the Food and Drug Administration-approved pharmacotherapies (bupropion, or nicotine products including gum, inhaler, nasal spray, or patch). Another change is the recommendation to continue treatment beyond 12 weeks, instead of the previously recommended six to 12 weeks. The new guidelines also strongly recommend starting varenicline even in patients who aren't yet ready to quit and in those with a comorbid psychiatric condition. For more, see http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365361/pdf/rccm.202005-1982ST.pdf.